Investor 2018-04-04T15:07:01+00:00

Long-term value through active ownership

CBC Investment Group started in 2009 in the midst of the financial crisis. The banks where struggling and start-ups, small and medium-sized businesses, suddenly saw their credit and credit promises turned into demands for quick repayment and empty words.  Serious and talented entrepreneurs risked seeing their ideas and businesses fail. It was like a response to this crisis as we started CBC Investment Group. We follow, analyze, evaluate and invest in the hottest global private equity trends. Our main focus is on the Nordic market. Most of our investments are made in co-investments with investment banks and other private equity players where long-term value can be enhanced through active ownership. With over 150,000 followers, we are today the largest qualified digital platform in the Nordic region for this form of capital investments.

What we are looking for:

  • Companies within Tech, Finance and the Life science industry

  • Companies preferably based in the Nordic region

Do you want to accelerate your business?

Partner with CBC for the right reasons

  • We have a passion for business and a strong commitment in the companies we invest in

  • We have solid member base who eagerly support our investments

  • Clear goals from us helps all parties drive the business towards success

  • We have the right experience and competence to help your company to reach expected results

Ongoing projects and investments

Pharmiva is a company within the area of Women’s Health, specifically addressing the growing problem of Antimicrobial Resistance or AMR. Their technology platform is based on HPLA, a combination of naturally occurring compounds, excluding development of resistance. The technology is about non-antibiotic treatment of intimate infections, STIs and related symptoms while reinforcing the body’s natural defense system. The patent pending technology is being used to develop a portfolio of products in several fields including pharmaceutical and consumer health categories.

300M women world-wide suffer from Bacterial Vaginosis (BV). Recurrence rates post treatment are typically 30-50% and antibiotics is the only recommended curative treatment. BV is also viewed as a gateway for STIs. Each year more than 450M people are infected by the most common Sexually Transmitted Indications (Gonorrhea, Chlamydia, Trichomonas). In Gonorrhea alone the number is 100M per year and is growing by 10% annually. Several strains of Gonorrhea bacteria are resistant and there is no effective treatment available.

Gradientech is developing a diagnostic system for ultra-rapid antibiotic susceptibility testing (AST). Antibiotic resistance is one of the biggest threats to global health and development today. Infections like blood poisoning (sepsis) are becoming harder to treat as antibiotics become less effective with rising resistance. Antibiotic resistant infections already today cause at least 25,000 deaths in Europe every year. According to the World Health Organization, new rapid diagnostic solutions for antibiotic susceptibility testing (AST) – tests determining which antibiotics an infected patient should be treated with – are highly needed in order to reduce misuse and overuse of antibiotics and limit the spread of resistance.

The IVD QuickMIC™ system in development by Gradientech can diagnose bacterial resistance in patients with suspected blood poisoning in only 2 hours. The chance of surviving blood poisoning decreases dramatically for each hour of incorrect antibiotic treatment, meaning that these samples are always the highest priority in the hospital laboratories.

Bulk thefts of passwords is one of the biggest problems in the IT industry today. The problem has existed for several decades and no one has managed to solve it completely. It has been shown that encryption, hash and salt do not provide sufficient protection for passwords because the only thing a hacker needs is to access the stored key/keys to decrypt the passwords along with the other stored encrypted data.

Authentico Technologies solve the issue with a new patented solution based on PUF (Physically Unclonable Function). The solution is based on a centralized hardware unit that companies connect to their servers. The keys are generated temporarily and no keys are stored within the server which means that the adversary needs physical access to attack the database. Even if the hashed passwords is downloaded, the attacker has no possibility to guess a password because the PUF device provides error outputs which are useless for a hacker.

Partners and co-investors